ArticleInfectious diseases and therapy2026

Safety, Pharmacokinetics, and Predicted Neutralizing Activity of the SARS-CoV-2 Monoclonal Antibody Sipavibart: Results from Little DIPPER and the SUPERNOVA Substudy.

Huixia Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.